186347-33-1

Basic information

• Product Name: 4-(2-chlorophenyl)-piperidine-4-carbonitrile hydrochloride
• Synonyms: 4-(2-chlorophenyl)-piperidine-4-carbonitrile hydrochloride
• CAS NO: 186347-33-1
• Molecular Weight: 257.163
• Mol File: 186347-33-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(2-chlorophenyl)-piperidine-4-carbonitrile hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-chlorophenyl)-piperidine-4-carbonitrile hydrochloride(186347-33-1)
• EPA Substance Registry System: 4-(2-chlorophenyl)-piperidine-4-carbonitrile hydrochloride(186347-33-1)

Safety Data

• Hazardous Substances Data: 186347-33-1(Hazardous Substances Data)

Upstream product

• 186347-31-9 4-(2-chlorophenyl)-4-cyanopiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 553635-34-0 (S)-4-(2-chlorophenyl)-1-[4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]piperidine-4-carbonitrile 
• 186347-35-3 4-(2-Chlorophenyl)-4-cyano-N-(3-[N-{1,1-dimethylethoxycarbonyl}]amino)propylpiperidine 

Relevant articles and documents

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS

-

ALPHA-1A ADRENERGIC RECEPTOR ANTAGONISTS

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.